← All indications
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Subtype terms (3)
More specific conditions that are subtypes of Liver Cirrhosis in the MeSH hierarchy.
- Liver Cirrhosis, Alcoholic
15 drugs (7 approved, 8 experimental)
- Liver Cirrhosis, Biliary
74 drugs (40 approved, 34 experimental)
- Liver Cirrhosis, Experimental
3 drugs approved
Drugs by status
Approved for this indication (5)
Phase 4 trials (72)
- simvastatin
- methylprednisolone
- avatrombopag
- angiotensin ii
- insulin glulisine
- ambrisentan
- cefotaxime
- norepinephrine
- tadalafil
- evogliptin
- empagliflozin
- entecavir
- tacrolimus
- insulin glargine
- naltrexone
- tenofovir
- bone marrow derived mesenchymal stem cells
- lactulose
- albumin (Human)
- insulin human
- warfarin
- incretin
- bone marrow derived autologous cd34+ selected cells
- magnesium oxide
- iohexol
- leucine
- ornithine aspartate
- somatostatin
- nadolol
- nitazoxanide
- +42 more
Phase 3 trials (67)
- obeticholic acid
- 131i-lipiodol
- allopurinol
- propofol
- calcium carbonate
- urea
- dabigatran
- cyclobenzaprine
- prednisone
- dextran
- elbasvir
- gabapentin
- gemcitabine
- ritonavir
- hydronidone
- Filgrastim
- insulin degludec
- ledipasvir
- methocarbamol
- immune globulin (human)
- sapropterin
- fluorescein
- growth hormone
- satavaptan
- tolvaptan
- rabeprazole
- pentoxifylline
- survodutide
- bifidobacterium infantis
- bifidobacterium breve
- +37 more
Phase 2 trials (84)
- edoxaban
- heparin
- adefovir dipivoxil
- vitamin e
- azd-3480
- sorafenib
- avenciguat
- bms-986036
- bone autograft
- bosentan
- pri-724
- cc-90001
- conivaptan
- danazol
- droxidopa
- durvalumab
- imatinib
- hepcortespenlisimut-l
- rosuvastatin
- emricasan
- ifetroban
- imiquimod
- carbamazepine
- autologous cd133+ stem cells
- lamivudine
- ursodeoxycholic acid
- oltipraz
- flumazenil
- pirfenidone
- pravastatin
- +54 more
Phase 1 trials (33)
- faldaprevir
- chitosan
- oxycodone
- eltrombopag
- hydroxychloroquine
- idarubicin
- lorazepam
- mgl-3196
- pasireotide
- colchicine
- acetaminophen
- lidocaine
- thrombopoietin
- siplizumab
- ondansetron
- autologous culture chondrocytes
- human placental derived stem cells
- liver nk cell
- tranexamic acid
- antithrombin iii (human)
- proglumide
- sargramostim
- tilarginine
- pemafibrate
- cilofexor
- fluoromisonidazole
- fap-2286
- allogenic hepatocytes
- 68ga-fapi-04
- pf-07202954
- +3 more
Other trials (67)
- mannitol
- metformin
- maltodextrin
- thalidomide
- vitamin d3
- spirulina
- desmopressin
- acetylcysteine
- darbepoetin alfa
- human fibrin
- epoetin
- chiglitazar
- clavulanate
- gadoxetate disodium
- calcium
- hydroxymethylbutyrate
- huangkui
- ivabradine
- interferon alpha-2a
- amoxicillin
- keyhole limpet hemocyanin
- lenvatinib
- mebendazole
- vitamin c
- cow milk
- daclatasvir
- potassium chloride
- praziquantel
- caffeine
- rep 2139
- +37 more
Organizations
Organization Involved with Phase 4 Indications (125)
- Bristol-Myers Squibb
- Gilead Sciences
- Schering-Plough
- Grifols
- Sanofi
- Intercept Pharmaceuticals
- Novartis
- Bayer
- GlaxoSmithKline
- Hannover Clinical Trial Center GmbH
- Norgine
- Samil Pharmaceutical Co., Ltd.
- Fundación Pública Andaluza
- University of Roma La Sapienza
- Dr. Falk Pharma GmbH
- Huazhong University of Science and Technology
- Qilu Hospital of Shandong University
- Aarhus University
- Maastricht University
- Hebei University
- Asian Institute Of Medical Sciences
- Asian-Pacific Alliance of Liver Disease, Beijing
- Azienda Ospedaliera San Camillo Forlanini
- Cairo University
- Changhai Hospital
- University of London
- China Academy of Chinese Medical Sciences
- Cornell University
- Harvard University
- Eastern Hepatobiliary Surgery Hospital
- +95 more
Organization Involved with Phase 3 Indications (92)
- AbbVie
- Axcan
- Roche
- Merck
- Pfizer
- Allergan
- BioVie Inc.
- Chugai
- Galectin Therapeutics Inc.
- PharmaKing
- Tobira Therapeutics, Inc.
- Otsuka
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Institutes of Health (NIH)
- French National Agency for Research on AIDS and Viral Hepatitis
- National Cancer Institute (NCI)
- National Center for Research Resources (NCRR)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Medical University of Graz
- Bambino Gesù Hospital and Research Institute
- Beijing Trendful Kangjian Medical Information Consulting Limited Company
- Casa Sollievo della Sofferenza IRCCS
- Case Western Reserve University
- Changi General Hospital
- Hospital Avicenne
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Kyoto University
- Mahidol University
- Pavol Jozef Safarik University
- +62 more
Organization Involved with Phase 2 Indications (120)
- Horizon Pharma
- Galecto Biotech
- Celgene
- Shire
- Bausch Health Companies
- Novo Nordisk
- Genentech
- Shionogi
- Albireo
- Biocad
- Cumberland Pharmaceuticals
- Fast Forward Pharmaceuticals
- FibroGen
- Gwo Xi Stem Cell Applied Technology Co., Ltd.
- Immunitor LLC
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
- Mallinckrodt
- NGM Biopharmaceuticals, Inc
- NovImmune SA
- Ocera Therapeutics
- Rebiotix Inc.
- Qilu Pharmaceutical Co., Ltd.
- S-Evans Biosciences Co.,Ltd.
- Shanghai Genomics, Inc.
- Synlogic
- A2 Healthcare Taiwan Corporation
- Boehringer Ingelheim
- CymaBay Therapeutics, Inc.
- Stempeutics Research Pvt Ltd
- +90 more
Organization Involved with Phase 1 Indications (28)
- Enanta Pharmaceuticals
- Sclnow Biotechnology Co., Ltd.
- Shenzhen Hornetcorn Bio-technology Company, LTD
- Sunshine Lake Pharma Co., Ltd.
- Pharmicell Co., Ltd.
- Central South University
- Johns Hopkins University
- Kanazawa University
- Medical College of Wisconsin
- Stanford University
- Universidad Complutense de Madrid
- University of Maryland
- University of Utah
- Nucleus Network Ltd
- OpenBiome
- Pharmaceutical Research Associates, Inc. (PRA)
- University of Texas at Houston
- Madrigal Pharmaceuticals
- Pennsylvania State University
- MHAPT Zarita Johanna University Hospital
- Florida Department of Health
- University of South China
- American College of Gastroenterology
- China Medical University
- Blade Therapeutics
- University of Burgundy
- Oswaldo Cruz Foundation
- OHARA Pharmaceutical Co., Ltd.
Organization Involved with Other Experimental Indications (40)
- Abbott
- Kaleido Biosciences
- Sequana Medical AG
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Corporal Michael J. Crescenz VA Medical Center
- Addis Ababa University
- University of Manitoba
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Instituto Mexicano del Seguro Social
- Loyola University
- Medical University of Warsaw
- National Cheng Kung University
- Sichuan University
- Sorlandet Hospital HF
- University of Louisville
- University of Oslo
- Zagazig University
- Taichung Veterans General Hospital
- Xiamen University
- Vanderbilt University
- Hospital of South West Jutland
- Government of Mexico
- Instituto Nacional de Ciencias Medicas de Nutricion
- Faculdade de Medicina de Botucatu
- Sao Paulo State University
- Ben Gurion University
- University of New South Wales
- Canadian Institutes of Health Research (CIHR)
- University of Agder
- +10 more